Trivalent Influenza Vaccine

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

Influenza Vaccine Trial in HIV Uninfected Pregnant Women

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Safe Administration of Flu Vaccine to Egg Allergic Children

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older